Companies: 10,795·Total market cap: $144.5T
AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTXNASDAQHealthcare● Active
$3.84
$-0.01(-0.18%)
Market Cap$105305978
P/E Ratio
52W High$6.91
52W Low$1
Overview

AN2 Therapeutics, Inc. (ANTX) Revenue

Annual & quarterly revenue history · segment & region breakdown

ANTX · revenue · updated Jun 9, 2026

Core revenue metrics

AN2 Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
22 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · AN2 Therapeutics, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
ANTX revenue by year · ANTX revenue history · ANTX annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income AN2 Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

AN2 Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from AN2 Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

ANTX revenue · 4 questions

ANTX's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

ANTX revenueANTX annual revenuewhat is ANTX revenueANTX TTM revenue

Source: FMP · AN2 Therapeutics, Inc. SEC filings · GAAP · AN2 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026